Prevention, Diagnosis & Treatment

Prevention, Diagnosis & Treatment

Bayer’s brands treat and prevent conditions to improve quality of life.

Pharma News

April 11, 2019

Bayer Announces Results of Sub-group Analysis for Vitrakvi® (larotrectinib) in Patients with NTRK Gene Fusion-Positive Metastatic Non-small Cell Lung Cancer (NSCLC)

Bayer today presented subgroup analysis data of patients with non-small cell lung cancer with neurotrophic receptor tyrosine kinase (NTRK) gene fusion treated with Vitrakvi® (larotrectinib).1...

Learn more
March 27, 2019

Bayer Data at AACR 2019 Underscores Company's Commitment to Advancing the Future of Cancer Care

Bayer will present research from its growing oncology portfolio at the American Association for Cancer Research (AACR) 2019 Annual Meeting, taking place March 29 to April 3 in Atlanta. The...

Learn more
February 15, 2019

Bayer to obtain full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and...

Learn more